Nice post There are some excellent opinions on

New Post Public Reply Private Reply Replies (1) Message Board
reallypeople?
752
Nice post


There are some excellent opinions on leronlimab from people with finance backgrounds. I’m a physician and an investment novice. But I work at large hospital with some of the highest number of Covid patients in my state. I’d like to lend my clinical perspective regarding leronlimab and Covid.

1. Covid is out of control. It is much more infectious than the flu. We were initially successful at flattening the curve, but as you can see, the curve is rising again across the country for multiple reasons. We are seeing more and more cases by the day. And while we may be able to slow things down periodically by going into quarantine, we will keep having spikes of this virus for the foreseeable future. Moreover, as we get into the fall and winter most experts predict a massive rise in the virus which could overwhelm our hospital system.

2. A vaccine isn’t coming any time soon. The fastest a vaccine has ever been developed was the mumps vaccine which took 4 years. Granted the entire world and pharmaceutical industry is working toward developing a vaccine but I’m not optimistic that we will have anything for at least another year. I’m also not sure how effective the vaccine will be- not to mention if it will be safe. Think about it. We’ve had influenza for over a hundred years. We spend millions of dollars a year developing a flu vaccine and it’s only partially effective at preventing us from getting sick. How are we going to develop a vaccine that is 100% effective against a virus that we’ve never seen before in 6-12 months? Even if we do, how will we make sure it’s safe and how will we produce enough for the entire country/world?

3. Our current treatments for Covid are next to useless.
We started out using hydroxychloroquine. It has no effect on clinical outcome which has been shown in multiple studies. Dexamethasone is a steroid. We use steroids often in patients with severe respiratory illnesses such as viral or bacterial pneumonia, especially when they develop ARDS- adult respiratory distress syndrome. ARDS is the result of multiple inflammatory mediators that effectively are turned on by an infection- i.e. pneumonia. When ARDS occurs the lungs become stiff and fill up with fluid. Oxygen cannot be effectively be delivered, even with a ventilator. Ultimately this is what kills patients with bad pneumonia and its what kills people with Covid. In Covid we are using dexamethasone but it’s really an act of desperation. It may help decrease inflammation in the lung but only partially. It also is risky to use because it has the side effect of suppressing the immune system further, which can make the infection get worse.
Remdesevir has almost no effect. In the main study quoted by the FDA, it only shortens illness from 15 to 11 days. It has no effect on survival and hasn’t been shown to suppress the virus. It also does nothing to prevent the cytokine storm that leads to ARDS. In my hospital we were one of the early adopters of Remdesevir and I’m just not seeing much of a difference.

4. Leronlimab seems tailor made to help decrease mortality from Covid. Cytokine storm is the main mechanism through which Covid kills patients. Think about a critically ill patient like you would a boulder on the edge of a cliff. Once the boulder gets rolling, the more damage it will cause. Leronlimab blocks inflammatory mediators from coming to the site of infection, effectively stopping the boulder in its tracks. As Dr. Patterson highlighted, it also helps reduce the viral load in the blood and helps restore the immune system so the patient can start to fight the infection on their own.

5. Leronlimab is safe as demonstrated in the HIV data.

6. The mechanism through which leronlimab shuts down inflammation could be useful in the treatment of many other diseases besides Covid.

Sorry for the long post but the more research I do on this drug the more I believe in it. I’m hoping to have it available soon so we can start using it on our patients. I think its going to change the entire course of this pandemic.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Roth Staffing's Commitment to Female Workforce Shines

Updated Category News Views 57

A Win for Roth Staffing in Workplace Equality When you hear about a company snagging the second spot on the 2026 Fortune Best Workplaces for Women list, you can't help but take notice. Roth Staffing Companies, nestled in Orange, California, just did that. It's not a fluke either—this is their 11th appearance on this prestigious list. If there were any doubts about the...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
Lennox Faces Pressures Amidst Strong Revenue Growth

Updated Category News Views 118

Revenue Surge but Margin Squeeze Out there in the land of HVAC, Lennox International (NYSE: LII) just dropped its third quarter earnings for 2026. Sure, they raked in a solid $1.6 billion—up a hearty 10%. But all that glitters ain't gold, and the company's operating income took a hit down to $312 million, shedding a cool five percent from last year. Challenges Weighing...

Continue Reading
Quad Sees Marginal Gains Amid Industry Challenges

Updated Category News Views 22

Treading Water with a Splash of Strategic Moves When you're in the thick of market shifts, sometimes it's not about big leaps but staying afloat with purpose. That's what Quad's recent financial release seems to hint at. A steady net sales figure hovering at $587 million for Q3 2026, barely a nudge compared to last year's numbers, sets the tone. It's not the fireworks...

Continue Reading
Fashion Sees Quality Trumping Price in Consumer Preferences

Updated Category News Views 75

Consumers Are Shifting Away from Price-First Mindset You could always count on shoppers looking for a bargain, right? Well, hold your horses, 'cause that train's rolling off the tracks. In today's fashion shuffle, good ol' quality and craftsmanship are giving low prices a run for their money. A study spearheaded by Boston Consulting Group (BCG) and Women's Wear Daily...

Continue Reading
Aktia Bank: Steady Ratings, Focused Expansion in Europe

Updated Category News Views 105

Aktia's Ratings Get a Boost In the world of financial minutiae, it was S&P Global Ratings that took the stage, buzzing about Aktia Bank Plc. The bank just had its ratings held steady with an outlook lift from negative to stable. That's like someone throwing you a life jacket when you're treading water; significant if you're trying to stay afloat, not so much if you've got...

Continue Reading
JumpCloud Tackles Compliance in the AI Era

Updated Category News Views 110

Compliance in a Changing Tech Landscape JumpCloud's stepping up in this brave new world riddled with tech and AI agents. They've got fresh platform features in their arsenal that'll keep organizations audit-ready day in and day out. Now, if you think compliance is just for the accountants to fret over, think again. In the agentic era, these advanced marvels—AI agents...

Continue Reading
New Era at Farah & Farah: Layla Farah Joins Firm

Updated Category News Views 38

Expanding the Family Legacy In the bustling city of Jacksonville, a fresh breeze has swept the corridors of the longtime legal fortress, Farah & Farah. Layla Farah, fresh off her swearing-in ceremony, has entered the ranks. It's not every day you see a purely family-driven outfit pulling together generations in such a dramatic way. Three kiddos now walking the halls of...

Continue Reading
Caesarstone Loses $67.7M Case Over Artificial Stone Risks

Updated Category News Views 83

A Demand for Accountability in the Courts A Los Angeles jury recently handed down a whopping $67.7 million verdict against Caesarstone Ltd. and its U.S. operations, marking a win for Dennys Rene Rivas Williams and his family. No sugarcoating here—this is a landmark case for artificial stone fabricators suffering from silicosis. The jury found Caesarstone entities a...

Continue Reading
Weibo Eyes Wall Street with Upcoming Q3 Earnings Reveal

Updated Category News Views 19

Setting The Stage For November Splash News just in, folks, and it’s got the potential to stir up a storm on Wall Street this coming November. Weibo Corporation—the big kahuna in China’s social media landscape—has put a date on the calendar to unfold their financial cards for Q3 2026. Mark November 17th, when all curtain on the Nasdaq:WB financial show will lift...

Continue Reading

Top 5 Most Recently Viewed Articles

Growing Demand for Myopia and Presbyopia Treatments Fueled by AI

Updated Category News Views 177

Understanding the Myopia and Presbyopia Treatment Market The myopia and presbyopia treatment market is on the verge of substantial growth as the demand for effective solutions rises. The global estimates suggest an anticipated growth of USD 9.76 billion during the period from 2024 to 2028, showcasing a considerable compound annual growth rate (CAGR) of 9.05%. This growth...

Continue Reading
Hape Group's Strategies for Thriving Through Global Tariff Changes

Updated Category News Views 220

Navigating the Challenges of Rising Tariffs in Toy Industry The global toy industry faces considerable turbulence due to soaring tariffs, particularly those impacting products manufactured in China. Over the years, these tariffs have risen dramatically, with some reaching as high as 145%. As a result, companies in this sector are grappling with unprecedented challenges,...

Continue Reading
Bill Gates' Strategic Investments Through the Gates Foundation

Updated Category News Views 276

Bill Gates' Investing Strategy With Berkshire Hathaway The Gates Foundation Trust has proudly expanded its portfolio, reaching a value of $47.78 billion. This substantial growth is largely attributed to its increasing stake in Berkshire Hathaway Inc. Class B shares, alongside a focused investment strategy revolving around only a handful of prominent stocks. Changes in the...

Continue Reading
Unraveling the Secret Symphony of Alston's Singing Mice

Updated Category News Views 143

The Fascinating World of Alston's Singing Mice COLD SPRING HARBOR, N.Y. — All mice are known for their squeaks; however, only a select few are recognized for their singing abilities. Among them is Scotinomys teguina, commonly referred to as Alston's singing mice, which originate from the lush cloud forests in Costa Rica. Cold Spring Harbor Laboratory (CSHL) is at the...

Continue Reading
NAVER Backs AIM for Safer AI, Eyes Security Gaps

Updated Category News Views 10

Around every corner, artificial intelligence is taking another leap and leaving some legacy in its wake. It seems only fitting that with all the tech wizardry, we also invite trouble right onto our doorsteps—AI trouble. That's where AIM Intelligence finds its niche, backed now by NAVER D2SF's investment, shaping up to be the unsung hero of AI security. The era of...

Continue Reading